Infinium Global Research has added
a new report on Biosimilar
Monoclonal Antibodies Market. The report presents analysis of global as
well as regional markets of biosimilar monoclonal antibodies market over the
period of 2016 to 2024. A monoclonal antibody is a type of protein made in the laboratory
that can bind to substances in the body, including cancer cells. A monoclonal
antibody is made so that it binds to only one substance to treat different
types of cancer. There are several types of monoclonal antibodies that are
being used to treat certain types of cancer. Laboratory production of
monoclonal antibodies is produced from clones of only one cell which means that
every monoclonal antibody produced by the cell is the same due to which they
are called as biosimilar monoclonal antibodies. Each monoclonal antibody
recognizes one particular protein. They work in different ways depending on the
protein they are targeting, hence different monoclonal antibodies are required
to be made to target different types of cancer.
The global biosimilar monoclonal antibodies market is driven by
the factors such as rising demand for biosimilar drugs owing to their cost
effectiveness, patent expiration of biologics, and prevalence of chronic
diseases among geriatric population. However, unfavorable government
regulations in developed economies and high cost associated with manufacturing
process are likely to act as a primary restraining factors affecting the global
biosimilar monoclonal antibodies market over the forecast period. Moreover,
emerging markets owing to relaxed regulations are expected to provide more
opportunities for the manufacturers of biosimilar drugs.
Among the geographies, Europe is an important market for
biosimilar monoclonal antibodies market globally due to favorable regulatory
policies designed by the European Medical Association (EMA) and since Europe
was the first region to draft guidelines for approval of biosimilar products. The
Asia pacific region accounted for the largest market size while North America
biosimilar monoclonal antibodies market is projected to grow at a CAGR of x.xx%
over the forecast period. Moreover, the growth matrix
presented by Infinium Global Research identifies the key investment markets in
the near future, this will not only help the companies to understand the
competitive position in the global biosimilar monoclonal antibodies market but
also make strategic decisions to capture the most lucrative markets in the near
future. The market size is presented in terms of value for the historic year
2016 and estimated for forecast period of 2018-2024.
Get
15% discount for early purchase of global biosimilar monoclonal antibodies
market report by clicking the following link, Use code IGRD15 to request the
discount in the given form
https://www.infiniumglobalresearch.com/reports/request-discount/72
The recent report identified that
Europe dominated the global biosimilar monoclonal antibodies market over the
last couple of years, while emerging markets of Asia-Pacific and Latin America
are anticipated to contribute significantly to the growth in the biosimilar
monoclonal antibodies market worldwide.
The report segments the global
biosimilar monoclonal antibodies market on the basis of Application and Drug
Class.
Global Biosimilar Monoclonal
Antibodies Market by Application
·
Diagnostic Applications
o
MAbs in Biochemical Analysis
§ Pregnancy
§ Cancers
§ Hormonal disorders
§ Infectious diseases
o
MAbs in Diagnostic Imaging
§ Cardiovascular diseases
§ Deep vein thrombosis (DVT)
§ Atherosclerosis
§ Cancers
§ Bacterial infections
·
Therapeutic Applications
o
MAbs as Direct Therapeutic Agents
o
MAbs as Targeting Agents in
Therapy
·
Protein Purification
Global Biosimilar Monoclonal
Antibodies Market by Drug Class
·
Rituximab
·
Infliximab
·
Abciximab
·
Trastuzumab
·
Adalimumab
·
Bevacizumab
Companies Profiled in the Report
·
Pfizer, Inc.
·
Novartis AG
·
Reliance Life Sciences
·
Allergan plc
